Figure 3

LOH and frameshift analysis was performed on sporadic RST that lost HLA class I expression. Only the tumors that presented with loss of one of the APM molecules or β2m were subjected to fragment analysis in their respective genes. The following repeats were analyzed for frameshift mutations: HLA A: 1 – 4^th exon 7(C), 2 – 5^th exon 3 (GGA); HLA – B: 3(GA) & 3(CA);β2m: 1 – 1^st exon 4(CT), 2 – 2^nd exon 4(GA) & 5(A), 3 – 2^nd exon 5(A); TAP1: 1 – 1^st exon 5(C), 2 – 3^rd exon 5(T), 3 – 8^th exon 5(G), 4 – 10^th exon 5(G), 5 – 11^th exon 6(G) & 5(A); TAP2: 1 – 2^nd exon 6(C), 2 – 9^th exon 5(G); Tapasin: 1 – 2^nd exon 5(G), 2 – 3^rd exon 5(C), 3 – 4^th exon 6(C), 4 – 5^th exon 5(G); Calnexin: 1 – 7^th exon 5(A), 2 – 8^th exon 5(A), 3 – 11^th exon 8(T); Calreticulin: 1 – 3^rd exon 5(G), 6^th exon 5(C); ERp57: 1 – 5^th exon 6(T), 2 – 6^th exon 6(A), 3 – 13^th exon 6(C); LMP2: 1 – 2^nd exon 5(G), 2 – 6^th exon 5(G); LMP7: 1^st exon 6(C) (key: ins – insertion; del – deletion; 0 – no mutation). LOH analysis of the 6p chromosome was also performed with the following markers: 1 – MOGc, 2 – D6S510, 3 – C125, 4 – C141, 5 – D6S2444, 6 – TAP1, 7 – M2426 (Key: Black – Loss of heterozygosity; Striped – non informative marker; White – Retention of heterozygosity).